Sanjeev Roy

625 total citations
24 papers, 460 citations indexed

About

Sanjeev Roy is a scholar working on Pathology and Forensic Medicine, Rheumatology and Immunology. According to data from OpenAlex, Sanjeev Roy has authored 24 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 6 papers in Rheumatology and 5 papers in Immunology. Recurrent topics in Sanjeev Roy's work include Multiple Sclerosis Research Studies (10 papers), Phytochemistry and Bioactive Compounds (4 papers) and Systemic Lupus Erythematosus Research (4 papers). Sanjeev Roy is often cited by papers focused on Multiple Sclerosis Research Studies (10 papers), Phytochemistry and Bioactive Compounds (4 papers) and Systemic Lupus Erythematosus Research (4 papers). Sanjeev Roy collaborates with scholars based in Germany, Switzerland and United States. Sanjeev Roy's co-authors include Vijay L. Kumar, Biswa Mohan Padhy, Rachna Sehgal, Vijay Kumar, Tim Mant, María Trojano, Martin Ullmann, Andrea Visconti, Volker Jean Wagner and Francesco Patti and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Annals of the Rheumatic Diseases.

In The Last Decade

Sanjeev Roy

23 papers receiving 416 citations

Peers

Countries citing papers authored by Sanjeev Roy

Since Specialization

Citations

This map shows the geographic impact of Sanjeev Roy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sanjeev Roy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sanjeev Roy more than expected).

Fields of papers citing papers by Sanjeev Roy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sanjeev Roy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sanjeev Roy. The network helps show where Sanjeev Roy may publish in the future.

Co-authorship network of co-authors of Sanjeev Roy

This figure shows the co-authorship network connecting the top 25 collaborators of Sanjeev Roy. A scholar is included among the top collaborators of Sanjeev Roy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sanjeev Roy. Sanjeev Roy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	RANDOMIZED, PLACEBO-CONTROLLED PHASE II STUDY OF ENPATORAN, A SMALL MOLECULE TOLL-LIKE RECEPTOR 7/8 INHIBITOR, IN CUTANEOUS LUPUS ERYTHEMATOSUS: RESULTS FROM COHORT A 2025 ·The Journal of Rheumatology ·David R. Pearson, Eric F. Morand, Joerg Wenzel, Richard Furie, Maria Dall’Era, Jorge Sánchez‐Guerrero, Sanjeev Roy, (unknown), Hans Gühring, Flavie Moreau, Victoria P. Werth	3
2	Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Kosalaram Goteti, (unknown), William R. Gillespie, Jonathan French, (unknown), Ying Li, (unknown), Sanjeev Roy, (unknown), Lisa J. Benincosa, Karthik Venkatakrishnan	6
3	Enpatoran in COVID‐19 pneumonia: Safety and efficacy results from a phase II randomized trial 2023 ·Clinical and Translational Science ·John E. McKinnon, (unknown), Cláudia Murta de Oliveira, Dongzi Yu, (unknown), Flavie Moreau, (unknown), (unknown), Sanjeev Roy, Amy Kao, (unknown)	10
4	1501 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and Phase II study design in patients with SLE and/or CLE (WILLOW) 2022 ·SHILAP Revista de lepidopterología ·Eric F. Morand, Victoria P. Werth, Andrew T. Bender, (unknown), (unknown), Bharat Vaidyanathan, (unknown), Melinda Przetak, Flavie Moreau, (unknown), Sanjeev Roy, David R. Pearson	0
5	Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis 2022 ·Neurology Neuroimmunology & Neuroinflammation ·Nicola De Stefano, Frederik Barkhof, Xavier Montalbán, Anat Achiron, Tobias Derfuß, Andrew Chan, Suzanne Hodgkinson, Alexandre Prat, Letizia Leocani, Klaus Schmierer, Finn Sellebjerg, Patrick Vermersch, Heinz Wiendl, Birgit Keller, (unknown), Sanjeev Roy, (unknown)	22
6	Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets 2022 ·Neurology Neuroimmunology & Neuroinflammation ·Heinz Wiendl, Klaus Schmierer, Suzanne Hodgkinson, Tobias Derfuß, Andrew Chan, Finn Sellebjerg, Anat Achiron, Xavier Montalbán, Alexandre Prat, Nicola De Stefano, Frederik Barkhof, Letizia Leocani, Patrick Vermersch, (unknown), (unknown), Kristina Holmberg, Ursula Boschert, Sanjeev Roy	25
7	Predicting disease activity in patients with multiple sclerosis: An explainable machine‐learning approach in the Mavenclad trials 2022 ·CPT Pharmacometrics & Systems Pharmacology ·Sreetama Basu, Alain Munafo, (unknown), Sanjeev Roy, Pascal Girard, Nadia Terranova	27
8	Investigating the Correlation Between Serum Neurofilament Light Chain (sNfL) Concentration and Magnetic Resonance Imaging (MRI)-Outcomes in Patients With a First Clinical Demyelinating Event in the REFLEX Trial (1116) 2021 ·Neurology ·Jens Kühle, David Leppert, Gıancarlo Comı, Nicola De Stefano, Ludwig Kappos, Mark S. Freedman, (unknown), Sanjeev Roy	1
9	Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis (1921) 2021 ·Neurology ·Nicola De Stefano, Frederik Barkhof, Xavier Montalbán, Anat Achiron, Tobias Derfuß, Andrew Chan, Suzanne Hodgkinson, Alexandre Prat, Letizia Leocani, Klaus Schmierer, Finn Sellebjerg, Patrick Vermersch, Heinz Wiendl, Birgit Keller, Sanjeev Roy	1
10	Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study (2235) 2021 ·Neurology ·Heinz Wiendl, Klaus Schmierer, Suzanne Hodgkinson, Tobias Derfuß, Andrew Chan, Finn Sellebjerg, Anat Achiron, Xavier Montalbán, Alexandre Prat, Nicola De Stefano, Frederik Barkhof, Letizia Leocani, Patrick Vermersch, (unknown), Sanjeev Roy, Ursula Boschert	10
11	Baseline Serum Neurofilament Light Chain Levels Predict Conversion to McDonald 2005 Multiple Sclerosis (MS) Within 2 Years of a First Clinical Demyelinating Event in Patients with MS (1908) 2021 ·Neurology ·Jens Kühle, David Leppert, Gıancarlo Comı, Nicola De Stefano, Ludwig Kappos, Mark Freedman, (unknown), Sanjeev Roy	1
12	Efficacy of Subcutaneous Interferon β-1a in Patients with a First Clinical Demyelinating Event in Reflex is Maintained After Application of the 2017 McDonald Criteria (1153) 2020 ·Neurology ·Mark S. Freedman, Ludwig Kappos, Gıancarlo Comı, Nicola De Stefano, Sanjeev Roy, (unknown)	1
13	A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY-MS Baseline Analysis (1487) 2020 ·Neurology ·Nicola De Stefano, Anat Achiron, Frederik Barkhof, Andrew Chan, Tobias Derfuß, Suzanne Hodgkinson, Letizia Leocani, Xavier Montalbán, Alexandre Prat, Klaus Schmierer, Finn Sellebjerg, Patrick Vermersch, Heinz Wiendl, Birgit Keller, Sanjeev Roy	2
14	Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS) 2020 ·Therapeutic Advances in Neurological Disorders ·Francesco Patti, Andrea Visconti, (unknown), Sanjeev Roy, María Trojano, (unknown)	36
15	Reduction of Risk of Secondary Progressive Multiple Sclerosis Within Two Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study 2020 ·Multiple Sclerosis and Related Disorders ·Patrick Vermersch, Gavin Giovannoni, Per Soelberg Sørensen, Kottil Rammohan, Stuart D. Cook, Birgit Keller, Sanjeev Roy	1
16	Protective effect of latex ofCalotropis procerain Freund's Complete Adjuvant induced monoarthritis 2008 ·Phytotherapy Research ·Vijay L. Kumar, Sanjeev Roy	29
17	Calotropis procera Latex Extract Affords Protection against Inflammation and Oxidative Stress in Freund's Complete Adjuvant-Induced Monoarthritis in Rats 2007 ·Mediators of Inflammation ·Vijay L. Kumar, Sanjeev Roy	73
18	A comparative study on the efficacy of rofecoxib in monoarticular arthritis induced by latex of Calotropis procera and Freund’s complete adjuvant 2006 ·Inflammopharmacology ·Vijay Kumar, Sanjeev Roy, (unknown), Biswa Mohan Padhy	32
19	Antioxidant and protective effect of latex of Calotropis procera against alloxan-induced diabetes in rats 2005 ·Journal of Ethnopharmacology ·Sanjeev Roy, Rachna Sehgal, Biswa Mohan Padhy, Vijay L. Kumar	131
20	Anti arthritic drugs. 1965 ·PubMed ·Sanjeev Roy	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact